Trial site
Leuven
- 10running trials
- 12closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- Lung cancer6 trials
- Colorectal cancer4 trials
- Acute myeloid leukaemia2 trials
- Melanoma2 trials
- Metastatic breast cancer2 trials
- Multiple sclerosis2 trials
- Myelodysplastic syndromes2 trials
- Aortic stenosis1 trial
- Childhood cancers1 trial
- Chronic myeloid leukaemia1 trial
- Diffuse large B-cell lymphoma1 trial
- Epilepsy1 trial
- and 13 more
- Phase
- Phase 38 trials
- Phase 25 trials
- Phase 14 trials
- Phase 1/23 trials
- Phase 41 trial
- Status
- Completed7 trials
- Active, not recruiting6 trials
- Terminated5 trials
- Recruiting4 trials
- Lead sponsor
- Novartis Pharmaceuticals22 trials
Running trials
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
Recruiting
Recruiting
Recruiting
Active, not recruiting
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Aortic stenosis1 recruiting
- Familial hypercholesterolaemia1 recruiting
- Heart failure1 recruiting
- High blood pressure1 recruiting
- Multiple sclerosis1 recruiting
- Pulmonary arterial hypertension1 recruiting
Closed trials
Completed
Terminated
Terminated
Terminated
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Completed
Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects
Terminated
Completed
Completed
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Completed
Terminated
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Completed
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026